Publications

†First/Co-first Author; *Corresponding author.   Google Scholar

Unpublished

• Han K†*, Cho YS†*, Takahashi M, Zhou X, Dobson H, Hutchings K, Wu Y, Na Y, Xie F, Crowther J, Nenwani M, Animasahun O, Wuchu F, Adren A, Wong H, Zhang L, Wan Z, Xu C, Dong K, Lee C, Jasewicz H, Wu Q, Camp E, Xu J, Kim Y, Xu Y, Schwendeman A, Xie Y, Lyssiotis CA, Clasby M, Nagrath D, Lei YL, Moon JJ*. Oral Nano-Delivery of a Gut Microbial Metabolite Enhances T Cell Stemness for Cancer Immunotherapy. (Nature Nanotechnology, Revision)

• Zhou X†, Ling X†, Sun X, Wan Z, Dwyer T, Moore T, Li Q, Dobson H, Wu Q, Kong X, Xie F, An X, Gan J, Wang K, Cho YS, Gong W, Dong K, Zhang J, Takahashi M, Xu C, Kodamasimham S, Xu J, Yuzbasiyan-Gurkan V, Chinn S, Schwendeman A, Glotzer SC, Lei YL, Moon JJ*. Intermetallic Nanoassemblies Potentiate Systemic STING Activation. (Science, Revision)

• Na Y†, Cho YS†*, Lee C, Camp E, Zhou X, Moon JJ*, Schwendeman A*. Restoration of tumor suppression using anti-HER2 lipid nanoparticle-mediated mRNA delivery to breast cancers. (In preparation) 

• Cho YS†*, Crowther J†, Takahashi M, Xie F, Xu J, Han K, Zhou X, Lyssiotis CA, Clasby M, Nagrath D, Dong K, Evans C, Moon JJ*. Gut microbiota-derived methyl ketone metabolite modulates Treg activity and suppresses autoimmune diseases. (In preparation) 

Prior Publications (2017-2025)

• Na Y†, Kinzer JL, Morrissette L, Cho YS, Shay B, Ford M, Schwedeman A*. Multimodal mass spectrometric characterization of structural microheterogeneity in rituximab reference and biosimilars. International Journal of Biological Macromolecules, 2025; 334: 149062
  
  

• Kodamasimham S†, Ju HH, Zhou X, Haggag Y, Huang C, Ha B, Salamevich D, Cho YS, Wu Q, Schwendeman SP*, Moon JJ*. Controlled delivery of STING agonist and manganese ion in injectable PLGA implants for enhanced cancer immunotherapy. Journal of Controlled Release, 2025; 389(10): 114410
  
  

• Cho YS†, Zhou X†, Wan Z, Crowther J, Takahashi M, Kodamasimham S, Wu Q, Phoo MT, Na Y, Han K, Li A, Schwedeman A, Schwedeman SP, Lei YL, Moon JJ*. Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle. Proceedings of the National Academy of Sciences, 2025; 122(45)
  
  

• Park SJ†, Cho YS, Lee JH, Kim SY, Park J, Kim HR, Byun Y*. An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer. Journal of Controlled Release, 2025; 389(10): 114380
  
  

• Cho YS†, Cho H†, Kim HR, Park SJ, Yeo JH, Ko YG, Lee J, Kim SY, Kim K, Byun Y*. Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. Journal of Controlled Release, 2024; 376: 829-841
  
  

• Kim HR, Park SJ, Cho YS, Ko YG, Kim SY, Byun Y*. Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate. Journal of Controlled Release, 2024; 375: 681-697
  
  

• Han K, Xie F, Animasahun O, Nenwani M, Kitamoto S, Kim Y, Phoo M, Xu J, Wuchu F, Omoloja K, Achreja A, Choppara S, Li Z, Gong W, Cho YS, Dobson H, Ahn J, Zhou X, Huang X, An X, Kim A, Xu Y, Wu Q, Lee SH, O'Konek JJ, Xie Y, Lei YL, Kamada N, Nagrath D, Moon JJ*. Inulin gel-based oral immunotherapy remodels the small intestinal microbiome and suppresses food allergy. Nature Materials, 2024; 23: 1444-1455
  
  

• Han K†, Cho YS†, Moon JJ*. Antibiotic nanoparticles boost antitumor immunity. Nature Biotechnology, 2024; 42: 1187-1188
  
  

• Kim HR, Park SJ, Cho YS, Moyo MK, Choi JU, Lee NK, Chung SW, Kweon S, Park J, Kim B, Ko YG, Yeo JH, Lee J, Kim SY, Byun Y*. Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer. Journal of Controlled Release, 2024; 372: 176-193
  
  

• Park SJ, Kweon S, Moyo MK, Kim HR, Choi JU, Lee NK, Maharjan R, Cho YS, Park JW*, Byun Y*. Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway. Biomaterials, 2024; 310: 122625
  
  

• Cho YS†, Han K†, Xu J†, Moon JJ*. Novel strategies for modulating the gut microbiome for cancer therapy. Advanced Drug Delivery Reviews, 2024; 210: 115332
  
  

• Jang Y†, Cho YS†, Kim A, Zhou X, Kim Y, Wan Z, Moon JJ*, Park H*. CXCR4-targeted macrophage-derived biomimetic hybrid vesicle nanoplatform for enhanced cancer therapy through co-delivery of manganese and doxorubicin. ACS Applied Materials & Interfaces, 2024; 16, 14: 17129-17144
  
  

• Cho YS†, Kim HR†, Park SJ, Chung SW, Ko YG, Yeo JH, Lee J, Kim SK, Choi JU, Kim SY*, Byun Y*. Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer. Biomaterials, 2022; 289: 121783

• Lee JC, Kim GC, Lee NK, Kim SH, Cho YS, Chung SW, Lee YS, Chang HW, Byun Y*, Kim SY*. Feedback amplification of senolysis using caspase-3-cleavable peptide-doxorubicin conjugate and 2DG. Journal of Controlled Release, 2022; 346: 158-168

• Kim HR†, Cho YS†, Chung SW, Choi JU, Ko YG, Park SJ, Kim SY, Byun Y*. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC. Journal of Controlled Release, 2022; 346: 136-147

• Cho YS†, Kim GC†, Lee HM, Kim B, Kim HR, Chung SW, Chang HW, Ko YG, Lee YS, Kim SW, Byun Y*, Kim SY*. Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer. Journal of Controlled Release, 2022; 344: 26-38

• Lee NK, Choi JU, Kim HR, Chung SW, Ko YG, Cho YS, Park SJ, Lee EJ, Kim SY, Kim IS*, Byun Y*. Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizaing nanocage therapeutics for immune-mediated elimination of colorectal cancer. Biomaterials, 2021; 277: 121105
  
  

• Choi JU, Kim JY, Chung SW, Lee NK, Park JH, Kweon SH, Cho YS, Kim HR, Lim SM, Park JW, Lee KC, Byun Y*. Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects. Journal of Controlled Release. 2021; 336: 181-191

• Cho YS†, Chung SW†, Kim HR, Won TH, Choi JU, Kim IS, Kim SY*, Byun Y*. The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug. Journal of Controlled Release. 2019; 296: 241-249

• Chung SW†, Cho YS†, Choi JU, Kim HR, Won TH, Kim SY*, Byun Y*. Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer. Biomaterials. 2019; 192: 109-117

• Chung SW, Choi JU, Cho YS, Kim HR, Won TH, Dimitrion P, Jeon OC, Kim SW, Kim IS, Kim SY*, Byun Y*. Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker. Advanced Science. 2018; 5(7): 1800368
  
  

• Chung SW, Kweon S, Lee BS, Kim GC, Mahmud F, Lee H, Cho YS, Choi JU, Jeon OC, Kim JW, Kim SW, Kim IS, Kim SY*, Byun Y*. Radiotherapy-assisted tumor selective metronomic oral chemotherapy. International Journal of Cancer. 2017; 141(9): 1912-1920